Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL)

19 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q2 2023.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 16 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 19.8M shares of 41.1M outstanding shares and own 48.11% of the company stock.
Largest 10 shareholders include Syncona Portfolio Ltd (11.1M shares), BAKER BROS. ADVISORS LP (2.56M shares), Artal Group S.A. (2.26M shares), Redmile Group, LLC (1.61M shares), Point72 Asset Management, L.P. (1.41M shares), RENAISSANCE TECHNOLOGIES LLC (450K shares), EDENTREE ASSET MANAGEMENT Ltd (100K shares), Forefront Analytics, LLC (74.8K shares), MORGAN STANLEY (72.8K shares), and CITADEL ADVISORS LLC (66.8K shares).
This table shows the top 16 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.